TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan

Stock News03-30

TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan, representing a year-on-year increase of 3.7%. Other income and gains reached 37.609 million yuan, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily consisted of government grants related to revenue, interest-free financing subsidies, and gains from the sale of a subsidiary. As a company focused on developing small-molecule targeted therapies for cancer treatment, TYK MEDICINES-B has established a pipeline comprising ten drug candidates. Building upon its existing organizational structure, the company is progressively expanding its commercial team to explore market potential. It continues to deepen the sales potential of its products and enhance brand promotion through participation in various academic conferences, industry collaborations, and platform partnerships, thereby diversifying its corporate branding initiatives and increasing its visibility within the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108363335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108363335","market":"us","top_or_hot":-1,"title":"TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan, representing a year-on-year increase of 3.7%. Other income and gains reached 37.609 million yuan, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily consisted of government grants related to revenue, interest-free financing subsidies, and gains from the sale of a subsidiary. As a company focused on developing small-molecule targeted therapies for cancer treatment, TYK MEDICINES-B has established a pipeline comprising ten drug candidates. Building upon its existing organizational structure, the company is progressively expanding its commercial team to explore market potential. It continues to deepen the sales potential of its products and enhance brand promotion through participation in various academic conferences, industry collaborations, and platform partnerships, thereby diversifying its corporate branding initiatives and increasing its visibility within the sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan, representing a year-on-year increase of 3.7%. Other income and gains reached 37.609 million yuan, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily consisted of government grants related to revenue, interest-free financing subsidies, and gains from the sale of a subsidiary. As a company focused on developing small-molecule targeted therapies for cancer treatment, TYK MEDICINES-B has established a pipeline comprising ten drug candidates. Building upon its existing organizational structure, the company is progressively expanding its commercial team to explore market potential. It continues to deepen the sales potential of its products and enhance brand promotion through participation in various academic conferences, industry collaborations, and platform partnerships, thereby diversifying its corporate branding initiatives and increasing its visibility within the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1108363335","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108363335","pubTimestamp":1774861599,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B"},"translate_title":"泰克医药-B公布全年业绩：研发开支升3.7%至约2.44亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1},"content_text":"TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan, representing a year-on-year increase of 3.7%. Other income and gains reached 37.609 million yuan, up 23.14% compared to the previous year. During the reporting period, other income and gains primarily consisted of government grants related to revenue, interest-free financing subsidies, and gains from the sale of a subsidiary. As a company focused on developing small-molecule targeted therapies for cancer treatment, TYK MEDICINES-B has established a pipeline comprising ten drug candidates. Building upon its existing organizational structure, the company is progressively expanding its commercial team to explore market potential. It continues to deepen the sales potential of its products and enhance brand promotion through participation in various academic conferences, industry collaborations, and platform partnerships, thereby diversifying its corporate branding initiatives and increasing its visibility within the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108363335","isCrawlerRequest":true}